Shares in Italian biotech company Gentium plunged more than 40 percent after it failed to convince European regulators of the benefits of its most advanced drug candidate for a rare liver condition.
http://www.reuters.com/article/2013/02/21/gentium-europe-idUSL4N0BL4M020130221?feedType=RSS&feedName=hotStocksNews
http://www.reuters.com/article/2013/02/21/gentium-europe-idUSL4N0BL4M020130221?feedType=RSS&feedName=hotStocksNews
No comments:
Post a Comment